Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harmony Biosciences Holdings (HRMY) Other Non-Current Liabilities: 2019-2025

Historic Other Non-Current Liabilities for Harmony Biosciences Holdings (HRMY) over the last 5 years, with Sep 2025 value amounting to $1.2 million.

  • Harmony Biosciences Holdings' Other Non-Current Liabilities fell 46.21% to $1.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.2 million, marking a year-over-year decrease of 46.21%. This contributed to the annual value of $1.9 million for FY2024, which is 7.68% down from last year.
  • Latest data reveals that Harmony Biosciences Holdings reported Other Non-Current Liabilities of $1.2 million as of Q3 2025, which was down 18.09% from $1.4 million recorded in Q2 2025.
  • Harmony Biosciences Holdings' 5-year Other Non-Current Liabilities high stood at $3.2 million for Q4 2021, and its period low was $831,000 during Q1 2021.
  • Moreover, its 3-year median value for Other Non-Current Liabilities was $1.8 million (2024), whereas its average is $1.8 million.
  • Per our database at Business Quant, Harmony Biosciences Holdings' Other Non-Current Liabilities surged by 270.40% in 2022 and then slumped by 49.52% in 2023.
  • Harmony Biosciences Holdings' Other Non-Current Liabilities (Quarterly) stood at $3.2 million in 2021, then decreased by 21.28% to $2.5 million in 2022, then declined by 15.67% to $2.1 million in 2023, then fell by 7.68% to $1.9 million in 2024, then slumped by 46.21% to $1.2 million in 2025.
  • Its Other Non-Current Liabilities stands at $1.2 million for Q3 2025, versus $1.4 million for Q2 2025 and $1.7 million for Q1 2025.